Declaration of competing financial interests
From the following article
New approaches to molecular cancer therapeutics
Ian Collins & Paul Workman
Nature Chemical Biology 2, 689 - 700 (2006)
doi:10.1038/nchembio840
Declaration: The authors have received research funding and/or have collaboration/licensing arrangements with Vernalis, Astex Therapeutics, Chroma Therapeutics, PIramed, Sareum, Cyclacel, Novartis, AstraZeneca, Genentech and GlaxoSmithKline. P.W. holds stock/options in Chroma Therapeutics, PIramed and Avalon Pharmaceuticals and is a consultant for Chroma Therapeutics, PIramed, Avalon Pharmaceuticals and Novartis.
